Enjoy complimentary customisation on priority with our Enterprise License!
Technavio’s market research analyst predicts the global postmenopausal osteoporosis drugs market to grow steadily at a CAGR of more than 4% over the forecast period. With the expected launch of promising pipeline molecules, the market for postmenopausal osteoporosis has a positive outlook in the coming years. The postmenopausal osteoporosis drugs market is characterized by the presence of promising late-stage molecules that are being developed by the major and upcoming players in this market. Some of the late-stage pipeline molecules that are envisaged to be launched during the forecast period are Tarsa Therapeutics’ TBRIA, romosozumab, Merck’ odanacatib (Phase III), and Radius Health’s abaloparatide (Phase III).
In this industry research report, the analysts have estimated factors such as the emergence of combination therapies to contribute to this market’s growth in the next four years. Anabolic and antiresorptive agents can significantly enhance bone density and strength as a combination therapy than as monotherapy. Clinical trials have been performed evaluating the effect of PTH1-34 or PTH1-84 in combination with antiresorptive drugs, including raloxifene, alendronate, and risedronate. Moreover, it has been observed that combining antiresorptive drugs with PTH or teriparatide has been successful in providing greater bone mineral density. For instance, Pfizer's Duavee is a combination of conjugated estrogens and bazedoxifene used in the treatment of postmenopausal osteoporosis with few side effects.
During 2015, the first line of therapy segment dominated the market and accounted for more than 64% of the market share. Optimal consumption of calcium and vitamin D is recommended as the first line of therapy to prevent and treat osteoporosis. Whereas, biphosphates are considered as a baseline preventive treatment for low bone density and glucocorticoid-induced osteoporosis in postmenopausal women. The second line of therapy is given when the initial treatment fails or is not tolerated by the patient, thereby aiding in the growth prospects of this market segment over the predicted period.
The Americas dominated the postmenopausal osteoporosis drugs market and accounted for nearly 46% of the market share during 2015. The US was the largest revenue contributor to the region because of the increased prevalence of the disease. Factors such as the increasing patient population and easy availability of drugs will contribute to the growth of this market in the region.
The global postmenopausal osteoporosis drugs market is highly competitive due to the presence of several international and regional vendors. The market is open to new players and has a lot of opportunities for growth. The competitive environment is expected to increase in due to the product extensions, new products, and new applications of the products and services provided.
Key vendors in this market are –
Other prominent vendors analyzed in this market research report are Allergan, Amgen Astellas Biopharm K.K., Deltanoid Pharmaceuticals, Noven, Novo Nordisk, Osteologix, Pfizer, PhytoHealth Corporation, Radius Health, Tarsa Therapeutics, UCB, Uni-Bio Science Group Limited, Upsher-Smith Laboratories, Watson Pharmaceuticals, and Zosano Pharma Inc.
Technavio also offers customization on reports based on specific client requirement.
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Key buying criteria
PART 07: Pipeline scenario
PART 08: Market landscape
PART 09: Market segmentation by therapeutic class
PART 10: Market segmentation by line of therapy
PART 11: Geographical segmentation
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
PART 18: Appendix
PART 19: Explore Technavio
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.